For traders with a bullish short-term outlook on the U.S. cannabis sector, the AdvisorShares MSOS Daily Leveraged ETF (NYSEARCA: MSOX) provides a specialised instrument designed to amplify daily upside movements in U.S. cannabis equities. MSOX is a leveraged ETF that seeks to deliver enhanced daily exposure to the AdvisorShares Pure US Cannabis ETF (MSOS), which tracks leading U.S. multi-state operators and cannabis-related companies. As with all leveraged products, effective use of MSOX requires a clear understanding of its daily reset mechanism, short holding horizon, and the impact of compounding on returns beyond a single trading session.

Leveraged Exposure to a Policy- and Catalyst-Driven Sector
The U.S. cannabis industry is highly sensitive to regulatory developments, legislative progress, earnings updates, capital market access, and shifts in investor risk appetite. Price movements can be sharp and event-driven, particularly around developments such as federal rescheduling discussions, SAFE Banking Act progress, state-level legalization initiatives, or quarterly results from major multi-state operators. In this environment, leveraged ETFs like MSOX allow traders to express high-conviction, tactical bullish views with magnified sensitivity to daily price movements across the sector rather than to a single stock.
MSOX is structured to deliver, before fees and expenses, approximately two times (+2x) the daily performance of MSOS. In practical terms:
Because leverage is reset daily, MSOX’s performance over periods longer than one day may diverge materially from simply twice the cumulative return of MSOS, particularly in volatile or range-bound markets.
Who Should Consider MSOX?
The AdvisorShares MSOS Daily Leveraged ETF is intended for active, sophisticated traders who are comfortable managing leveraged exposures and monitoring positions closely. It is not designed for long-term investors or buy-and-hold strategies.
Common tactical use cases include:
Due to daily reset and compounding effects, MSOX requires active oversight, as multi-day holding periods can lead to outcomes that differ significantly from the expected +2x cumulative performance of MSOS.
Key Risks and Strategic Considerations
Before trading MSOX, investors should carefully evaluate the following:
Price Chart & Technical Summary


Conclusion
MSOX is a precision trading instrument designed to provide amplified daily long exposure to the U.S. cannabis sector via MSOS. For experienced traders who understand leveraged ETF mechanics and the policy-driven volatility inherent in cannabis equities, MSOX can be an effective tool for expressing short-term bullish views. However, its daily reset structure, sensitivity to compounding, and exposure to a highly volatile sector necessitate disciplined position sizing, active monitoring, and a clear understanding of leveraged product behavior across varying market conditions.
This report (“Report”) has been issued by Kalkine New Zealand Limited (FSP691351) (NZBN:9429047678101) (“Kalkine”). Kalkine is a Financial Advice Provider (“FAP”) and is authorised by a Class 1 Financial Advice Provider Licence issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity securities, managed funds and other managed investment schemes and other financial advice products. The recommendations and opinions in this Report and on Kalkine website do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine).
The information in this Report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its reports (including this Report), newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not issue, sell or deal in any financial products. The information in this Report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products. Kalkine is not responsible for, and does not guarantee, the performance of, or returns on, any investments mentioned in this Report.
This Report may contain information on past performance of particular investments. Past performance is not a reliable indicator of future performance. Returns stated do not take into account transaction costs and taxes.
Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website. Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.
Copyright 2025 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Report, or its content, may be reproduced in any form without our prior consent.
Past performance is not a reliable indicator of future performance.